Literature DB >> 12083297

Model-predictive control of hyperthermia treatments.

Dhiraj Arora1, Mikhail Skliar, Robert B Roemer.   

Abstract

A model-predictive controller (MPC) of the thermal dose in hyperthermia cancer treatments has been developed and evaluated using simulations with one-point and one-dimensional models of a tumor. The developed controller is the first effort in: 1) the application of feedback control to pulsed, high-temperature hyperthermia treatments; 2) the direct control of the treatment thermal dose rather than the treatment temperatures; and 3) the application of MPC to hyperthermia treatments. Simulations were performed with different blood flow rates in the tumor and constraints on temperatures in normal tissues. The results demonstrate that 1) thermal dose can be controlled in the presence of plant-model mismatch and 2) constraints on the maximum allowable temperatures in normal tissue and/or the pulsed power magnitude can be directly incorporated into MPC and met while delivering the desired thermal dose to the tumor. For relatively high blood flow rates and low transducer surface intensities--factors that limit the range of temperature variations in the tumor, the linear MPC, obtained by piece-wise linearization of the dose-temperature relationship, provides an adequate performance. For large temperature variations, the development of nonlinear MPC is necessary.

Entities:  

Mesh:

Year:  2002        PMID: 12083297     DOI: 10.1109/TBME.2002.1010846

Source DB:  PubMed          Journal:  IEEE Trans Biomed Eng        ISSN: 0018-9294            Impact factor:   4.538


  10 in total

1.  Pilot point temperature regulation for thermal lesion control during ultrasound thermal therapy.

Authors:  H L Liu; Y Y Chen; J Y Yen; W L Lin
Journal:  Med Biol Eng Comput       Date:  2004-03       Impact factor: 2.602

Review 2.  A review on numerical modeling for magnetic nanoparticle hyperthermia: Progress and challenges.

Authors:  Izaz Raouf; Salman Khalid; Asif Khan; Jaehun Lee; Heung Soo Kim; Min-Ho Kim
Journal:  J Therm Biol       Date:  2020-06-17       Impact factor: 2.902

3.  Minimum-time thermal dose control of thermal therapies.

Authors:  Dhiraj Arora; Mikhail Skliar; Robert B Roemer
Journal:  IEEE Trans Biomed Eng       Date:  2005-02       Impact factor: 4.538

4.  Direct thermal dose control of constrained focused ultrasound treatments: phantom and in vivo evaluation.

Authors:  Dhiraj Arora; Daniel Cooley; Trent Perry; Mikhail Skliar; Robert B Roemer
Journal:  Phys Med Biol       Date:  2005-04-06       Impact factor: 3.609

5.  Identification of reduced-order thermal therapy models using thermal MR images: theory and validation.

Authors:  Ran Niu; Mikhail Skliar
Journal:  IEEE Trans Med Imaging       Date:  2012-04-16       Impact factor: 10.048

6.  Homologous recombination research is heating up and ready for therapy.

Authors:  Simon N Powell; Lisa A Kachnic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-03       Impact factor: 11.205

7.  Kalman filtered MR temperature imaging for laser induced thermal therapies.

Authors:  D Fuentes; J Yung; J D Hazle; J S Weinberg; R J Stafford
Journal:  IEEE Trans Med Imaging       Date:  2011-12-22       Impact factor: 10.048

8.  Sonication strategies toward volumetric ultrasound hyperthermia treatment using the ExAblate body MRgFUS system.

Authors:  Kisoo Kim; Muhammad Zubair; Matthew Adams; Chris J Diederich; Eugene Ozhinsky
Journal:  Int J Hyperthermia       Date:  2021       Impact factor: 3.914

9.  Development of robust/predictive control strategies for image-guided ablative treatments using a minimally invasive ultrasound applicator.

Authors:  Amin Yazdanpanah Goharrizi; Raymond Kwong; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2014-10-14       Impact factor: 3.914

10.  Tumor selective hyperthermia induced by short-wave capacitively-coupled RF electric-fields.

Authors:  Mustafa Raoof; Brandon T Cisneros; Stuart J Corr; Flavio Palalon; Steven A Curley; Nadezhda V Koshkina
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.